QC
ALLO icon

Quadrature Capital’s Allogene Therapeutics ALLO Stock Holding History

Quadrature Capital’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$438K Buy
210,493
+129,049
+158% +$283K ﹤0.01% 1058
2026
Q1 		$199K Sell
81,444
-192,972
-70% -$387K ﹤0.01% 1125
2025
Q4 		$376K Buy
274,416
+36,479
+15% +$48.1K ﹤0.01% 771
2025
Q3 		$294K Buy
237,937
+193,887
+440% +$231K ﹤0.01% 676
2025
Q2 		$50K Buy
44,050
+10,059
+30% +$13.4K ﹤0.01% 946
2025
Q1 		$49.5K Buy
+33,991
New +$64.1K ﹤0.01% 978

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Quadrature Capital's ALLO Position: Q2 2026 in Review

Quadrature Capital increased its Allogene Therapeutics (ALLO) stake by 158% in Q2 2026, buying an estimated $283K and bringing the position to 210,493 shares worth $438K. The position accounts for ﹤0.01% of the portfolio, ranked #1058.

Quadrature Capital first reported a position in ALLO in Q1 2025 and has held it in 6 quarters since. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Quadrature Capital held 210,493 shares of Allogene Therapeutics worth $438K as of Q2 2026.
  • Quadrature Capital bought 129,049 Allogene Therapeutics shares in Q2 2026, an estimated $283K.
  • Allogene Therapeutics made up ﹤0.01% of Quadrature Capital's portfolio in Q2 2026, its #1058 holding.
  • Quadrature Capital first reported a position in Allogene Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.